Taylor Sandison
Chief Tech/Sci/R&D Officer at CIDARA THERAPEUTICS, INC.
Net worth: 437 777 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jeffrey Stein | M | 69 |
Trius Therapeutics, Inc.
 Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 17 years |
| Theodore Schroeder | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 15 years |
| Shane Ward | M | 49 | 3 years | |
| Les Tari | M | 57 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 17 years |
| Daniel Burgess | M | 62 | 10 years | |
| Pamela Craig | F | 67 | 9 years | |
| Preetam Shah | M | 51 | 3 years | |
| Carin Canale-Theakston | F | 50 | 3 years | |
| Bonnie Bassler | M | 61 | 3 years | |
| Chrysa Mineo | F | 59 | 6 years | |
| Paul Rothman | M | 66 | 9 years | |
| Daniel T. Chiu | M | 52 |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 18 years |
| Benjamin Ware Starnes | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 17 years |
| Sarah Halton | F | 64 |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 17 years |
| Carmen Betancourt | F | - | 10 years | |
| Alan Leong | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 23 years |
| Laura A. Navalta | F | - | 7 years | |
| Desney Tan | M | 48 |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 17 years |
| Brooke Hinkson | F | - | 9 years | |
| Allison Lewis | F | - | 9 years | |
| Nicole Davarpanah | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Perez | M | 59 | 15 years | |
| Matthew W. Onaitis | M | 53 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 3 years |
| Michael Bonney | M | 65 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 20 years |
| Michael Tomsicek | M | 58 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 years |
| Thomas DesRosier | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 2 years |
| Matthew Pruis | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 6 years |
| Michael Bell | M | 55 |
Novartis Vaccines & Diagnostics, Inc.
 Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ. | 6 years |
| John Schmid | M | 60 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 9 years |
| Benjamin FEREIDOON Mahdavi | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 7 years |
| Michael Morneau | M | 58 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 years |
| Neil Abdollahian | M | 51 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 11 years |
| Ronald Kei Ching Chan | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 5 years |
| Colonel F. Betz | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 8 years |
| Trisha K. Yukawa | F | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 7 years |
| Jessica Oien | F | 53 | 3 years | |
| Sarah Slater Power | F | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 6 years |
| Paul Truex | M | 55 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 years |
| William Little | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 5 years |
| Jennifer Moreland | F | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 5 years |
| Paul Daruwala | M | 55 | 8 years | |
| Brian Piekos | M | 49 | 5 years | |
| Marc Wilson | M | 45 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 8 years |
| JJ Lin | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 6 years |
| Trent Erickson | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 4 years |
| Nina Kjellson | F | 49 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 years |
| Daniel Bensen | M | 49 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 11 years |
| Thomas M Betts | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 5 years |
| Teri Loxam | F | 52 | 4 years | |
| Geoff A. Urbina | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 2 years |
| Amy Elmendorf Tucker | F | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 8 years |
| Brian Atwood | M | 71 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 years |
| Nancy Hutson | M | 74 | 7 years | |
| Michael Abbott | M | 50 |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 3 years |
| Scott Rocklage | M | 69 | 6 years | |
| Lonnie Moulder | M | 66 | 5 years | |
| Brendan M. O'Leary | M | 52 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 3 years |
| Mark Corrigan | M | 66 | 7 years | |
| Risa Stack | M | 55 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 years |
| Dino Vendetti | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 10 years |
| Desikachari Nadadur | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 8 years |
| Karin Eastham | F | 74 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 years |
| Dave Matter | M | 54 |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 4 years |
| Timothy Franson | M | 72 | 9 years | |
| Joseph Romanelli | M | 50 | 19 years | |
| David Gollaher | M | 74 | 6 years | |
| Alison Lawton | F | 62 | 2 years | |
| Patrick Volkert Vink | M | 60 | 3 years | |
| Gene Chen | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 5 years |
| Giselle Alvarado | F | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 4 years |
| Sharon L. Nelson | F | 76 |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 3 years |
| David Leimgruber | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 3 years |
| Tasheda Navarro | F | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 4 years |
| Nick Haupt | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 2 years |
| Kevin Yu | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | - |
| Christopher Anderson | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 2 years |
| Grace Lee | F | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 4 years |
| Paul Luce | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 4 years |
| Seth Lobree | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 4 years |
| Aaron Dickie | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 4 years |
| Andy Call | M | 48 |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 3 years |
| Amy Harris | F | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 4 years |
| Melissa Siska Juminto | F | 36 |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 4 years |
| David Zhao | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 3 years |
| Greg Badros | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 4 years |
| Mike Liu | M | 58 |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 2 years |
| Gary Stephens | M | 61 |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 4 years |
| Sam Whiting | M | 58 |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 6 years |
| Sang-Ik Jeong | M | 44 |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 6 years |
| Hashim Awdeh Al-Fadel Al-Fadel | M | 70 |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 3 years |
| Kurtis Heimerl | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 5 years |
| Travis Fairchild | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 2 years |
| M. Joan Alexander | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 6 years |
| Brian Maass | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 4 years |
| Seth Fischer | M | 68 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | - |
| Sunil Gordhan Hirani | M | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 4 years |
| Vlad Polyanskiy | M | 48 |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 2 years |
| Debbie D. Nye | F | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 3 years |
| Jen L. Neumann | F | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 3 years |
| Xiao jie Li | F | 43 |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Taylor Sandison
- Personal Network